These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 36460340

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43. (68)Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer.
    Sachpekidis C, Eder M, Kopka K, Mier W, Hadaschik BA, Haberkorn U, Dimitrakopoulou-Strauss A.
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1288-99. PubMed ID: 26753602
    [Abstract] [Full Text] [Related]

  • 44. Solitary rib lesions showing prostate-specific membrane antigen (PSMA) uptake in pre-treatment staging 68 Ga-PSMA-11 positron emission tomography scans for men with prostate cancer: benign or malignant?
    Chen MY, Franklin A, Yaxley J, Gianduzzo T, McBean R, Wong D, Tatkovic A, McEwan L, Walters J, Kua B.
    BJU Int; 2020 Sep; 126(3):396-401. PubMed ID: 32592330
    [Abstract] [Full Text] [Related]

  • 45. Does bone scintigraphy still have a role in the era of 68 Ga-PSMA PET/CT in prostate cancer?
    Simsek DH, Sanli Y, Civan C, Engin MN, Isik EG, Ozkan ZG, Kuyumcu S.
    Ann Nucl Med; 2020 Jul; 34(7):476-485. PubMed ID: 32394269
    [Abstract] [Full Text] [Related]

  • 46. 68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy.
    Ceci F, Castellucci P, Graziani T, Farolfi A, Fonti C, Lodi F, Fanti S.
    Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):31-39. PubMed ID: 30350010
    [Abstract] [Full Text] [Related]

  • 47. Comparison of Bone Uptake in Bone Scan and Ga-68 PSMA PET/CT Images in Patients with Prostate Cancer.
    Acar E, Bekiş R, Polack B.
    Curr Med Imaging Rev; 2019 Jan; 15(6):589-594. PubMed ID: 32008568
    [Abstract] [Full Text] [Related]

  • 48. 68 Ga-PSMA-PET for radiation treatment planning in prostate cancer recurrences after surgery: Individualized medicine or new standard in salvage treatment.
    Habl G, Sauter K, Schiller K, Dewes S, Maurer T, Eiber M, Combs SE.
    Prostate; 2017 Jun; 77(8):920-927. PubMed ID: 28317152
    [Abstract] [Full Text] [Related]

  • 49. Establishment and prospective validation of an SUVmax cutoff value to discriminate clinically significant prostate cancer from benign prostate diseases in patients with suspected prostate cancer by 68Ga-PSMA PET/CT: a real-world study.
    Jiao J, Kang F, Zhang J, Quan Z, Wen W, Zhao X, Ma S, Wu P, Yang F, Guo W, Yang X, Yuan J, Shi Y, Wang J, Qin W.
    Theranostics; 2021 Jun; 11(17):8396-8411. PubMed ID: 34373749
    [Abstract] [Full Text] [Related]

  • 50. Comparison of preoperative locoregional Ga-68 PSMA-11 PET-CT and mp-MRI results with postoperative histopathology of prostate cancer.
    Yilmaz B, Turkay R, Colakoglu Y, Baytekin HF, Ergul N, Sahin S, Tugcu V, Inci E, Tasci AI, Cermik TF.
    Prostate; 2019 Jun; 79(9):1007-1017. PubMed ID: 31012125
    [Abstract] [Full Text] [Related]

  • 51. Consecutive Prostate-Specific Membrane Antigen (PSMA) and Antigen Receptor (AR) PET Imaging Shows Positive Correlation with AR and PSMA Protein Expression in Primary Hormone-Naïve Prostate Cancer.
    Al Jalali V, Wasinger G, Rasul S, Grubmüller B, Wulkersdorfer B, Balber T, Mitterhauser M, Simon J, Hacker M, Shariat S, Egger G, Zeitlinger M.
    J Nucl Med; 2023 Jun; 64(6):863-868. PubMed ID: 36657982
    [Abstract] [Full Text] [Related]

  • 52. [68Ga]PSMA PET/CT Improves Initial Staging and Management Plan of Patients with High-Risk Prostate Cancer.
    Hirmas N, Al-Ibraheem A, Herrmann K, Alsharif A, Muhsin H, Khader J, Al-Daghmin A, Salah S.
    Mol Imaging Biol; 2019 Jun; 21(3):574-581. PubMed ID: 30215174
    [Abstract] [Full Text] [Related]

  • 53. Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence.
    Uprimny C, Kroiss AS, Fritz J, Decristoforo C, Kendler D, von Guggenberg E, Nilica B, Maffey-Steffan J, di Santo G, Bektic J, Horninger W, Virgolini IJ.
    Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1647-1655. PubMed ID: 28589253
    [Abstract] [Full Text] [Related]

  • 54. Detection Efficacy of Hybrid 68Ga-PSMA Ligand PET/CT in Prostate Cancer Patients with Biochemical Recurrence After Primary Radiation Therapy Defined by Phoenix Criteria.
    Einspieler I, Rauscher I, Düwel C, Krönke M, Rischpler C, Habl G, Dewes S, Ott A, Wester HJ, Schwaiger M, Maurer T, Eiber M.
    J Nucl Med; 2017 Jul; 58(7):1081-1087. PubMed ID: 28209912
    [Abstract] [Full Text] [Related]

  • 55. PSA-stratified detection rates for [68Ga]THP-PSMA, a novel probe for rapid kit-based 68Ga-labeling and PET imaging, in patients with biochemical recurrence after primary therapy for prostate cancer.
    Derlin T, Schmuck S, Juhl C, Zörgiebel J, Schneefeld SM, Walte ACA, Hueper K, von Klot CA, Henkenberens C, Christiansen H, Thackeray JT, Ross TL, Bengel FM.
    Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):913-922. PubMed ID: 29308527
    [Abstract] [Full Text] [Related]

  • 56. 68Ga-PSMA PET/CT in the evaluation of bone metastases in prostate cancer.
    Sachpekidis C, Bäumer P, Kopka K, Hadaschik BA, Hohenfellner M, Kopp-Schneider A, Haberkorn U, Dimitrakopoulou-Strauss A.
    Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):904-912. PubMed ID: 29362859
    [Abstract] [Full Text] [Related]

  • 57. Prospective study on the effect of short-term androgen deprivation therapy on PSMA uptake evaluated with 68Ga-PSMA-11 PET/MRI in men with treatment-naïve prostate cancer.
    Ettala O, Malaspina S, Tuokkola T, Luoto P, Löyttyniemi E, Boström PJ, Kemppainen J.
    Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):665-673. PubMed ID: 31879814
    [Abstract] [Full Text] [Related]

  • 58. 68Ga-PSMA PET/CT in Patients with Rising Prostatic-Specific Antigen After Definitive Treatment of Prostate Cancer: Detection Efficacy and Diagnostic accuracy.
    Hamed MAG, Basha MAA, Ahmed H, Obaya AA, Afifi AHM, Abdelbary EH.
    Acad Radiol; 2019 Apr; 26(4):450-460. PubMed ID: 29935970
    [Abstract] [Full Text] [Related]

  • 59. The roles of 68 Ga-PSMA PET/CT and 18 F-FDG PET/CT imaging in patients with triple-negative breast cancer and the association of tissue PSMA and claudin 1, 4, and 7 levels with PET findings.
    Arslan E, Ergül N, Beyhan E, Erol Fenercioglu Ö, Sahin R, Cin M, Battal Havare S, Can Trabulus FD, Mermut Ö, Akbas S, Fikret Çermik T.
    Nucl Med Commun; 2023 Apr 01; 44(4):284-290. PubMed ID: 36756767
    [Abstract] [Full Text] [Related]

  • 60. Predicting Outcomes of Indeterminate Bone Lesions on 18F-DCFPyL PSMA PET/CT Scans in the Setting of High-Risk Primary or Recurrent Prostate Cancer.
    Phelps TE, Harmon SA, Mena E, Lindenberg L, Shih JH, Citrin DE, Pinto PA, Wood BJ, Dahut WL, Gulley JL, Madan RA, Choyke PL, Turkbey B.
    J Nucl Med; 2023 Mar 01; 64(3):395-401. PubMed ID: 36265908
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.